Powered by: Motilal Oswal
2025-11-10 03:15:54 pm | Source: Accord Fintech
Torrent Pharmaceuticals zooms on reporting 30% rise in Q2 consolidated net profit
Torrent Pharmaceuticals zooms on reporting 30% rise in Q2 consolidated net profit

Torrent Pharmaceuticals is currently trading at Rs. 3818.10, up by 238.60 points or 6.67% from its previous closing of Rs. 3579.50 on the BSE.

The scrip opened at Rs. 3693.35 and has touched a high and low of Rs. 3835.15 and Rs. 3632.00 respectively. So far 49066 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3,835.15 on 10-Nov-2025 and a 52 week low of Rs. 2,891.45 on 03-Mar-2025.

Last one week high and low of the scrip stood at Rs. 3835.15 and Rs. 3532.85 respectively. The current market cap of the company is Rs. 129536.61 crore.

The promoters holding in the company stood at 68.31%, while Institutions and Non-Institutions held 25.20% and 6.49% respectively.

Torrent Pharmaceuticals has reported 29.78% jump in its net profit at Rs 597 crore for second quarter ended September 30, 2025 as compared to Rs 460 crore for the same quarter in the previous year. The total income of the company increased by 12.69% at Rs 2,735 crore for Q2FY26 as compared to Rs 2,427 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 30.46% rise in its net profit at Rs 591 crore for Q2FY26 as compared to Rs 453 crore for the same quarter in the previous year. The total income of the company increased by 13.99% at Rs 3,275 crore for Q2FY26 as compared to Rs 2,873 crore for the corresponding quarter previous year.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here